MAPT and Alzheimer disease: In particular, using GA to inhibit glycolysis, and increase AGEs level, well recapitulates the AD human features, in which the accumulation of AGEs and subsequent activation of the RAGE receptor is often described, leading to the activation of the amyloidogenic pathway and Tau hyperphosphorylation [1,38,39,40,41].